Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis

BACKGROUND: Radiofrequency ablation (RFA) is considered as a convenient treatment with mild damage in treating recurrent hepatocellular carcinoma (RHCC). However, for patients with high risk of progression after RFA still needs new strategies to decrease the repeat recurrence. METHODS: A total of 46...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Qunfang, Wang, Xiaohui, Li, Ruixia, Wang, Chenmeng, Wang, Juncheng, Xie, Xiaoyan, Li, Yali, Li, Shaoqiang, Mao, Xianhai, Liang, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article―Liver, Pancreas, and Biliary Tract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392709/
https://www.ncbi.nlm.nih.gov/pubmed/35816221
http://dx.doi.org/10.1007/s00535-022-01895-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392709/
https://www.ncbi.nlm.nih.gov/pubmed/35816221
http://dx.doi.org/10.1007/s00535-022-01895-3

Ejemplares similares